This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (1)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in JAMA  Topic Collections  • Infectious Diseases, Other  • Drug Therapy  • Drug Therapy, Other  • Infectious Diseases  • Alert me on articles by topic  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: In their study of laboratory isolates, Dr Naimi and colleagues¹ found that community-acquired methicillin-resistant Staphylococcus aureus (MRSA) had different clinical, demographic, and microbiological characteristics than health care–associated MRSA. The authors acknowledged that their study was not population-based. Many studies on this topic have not been population-based and the majority have not tried to measure community-associated MRSA prevalence.² Some have suggested that control of health care–associated MRSA, which Naimi et al found to account for a large majority of MRSA isolates in Minnesota, may be more difficult if MRSA becomes widespread in the community.³ Prevalence studies, preferably population-based, are needed to determine how widespread MRSA is in communities and nations. Available prevalence studies suggest that MRSA is not yet widespread in the United States or Europe.² In a population-based study of a Native American population, focusing on a significant increase in community MRSA infections in which MRSA was . . . [Full Text of this Article]

Cassandra D. Salgado, MD, MS
salgadoc@mail.ecu.edu
Brody School of Medicine
East Carolina University
Greenville, NC

Barry M. Farr, MD, MSc
University of Virginia Health System
Charlottesville

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLES

Community-Acquired Methicillin-Resistant Staphylococcus aureus—Reply
Kathleen LeDell, Timothy Naimi, Scott Fridkin, and Ruth Lynfield
JAMA. 2004;291(16):1961.
EXTRACT | FULL TEXT  

Comparison of Community- and Health Care–Associated Methicillin-Resistant Staphylococcus aureus Infection
Timothy S. Naimi, Kathleen H. LeDell, Kathryn Como-Sabetti, Stephanie M. Borchardt, David J. Boxrud, Jerome Etienne, Susan K. Johnson, Francois Vandenesch, Scott Fridkin, Carol O'Boyle, Richard N. Danila, and Ruth Lynfield
JAMA. 2003;290(22):2976-2984.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Efficacy of Iclaprim against Wild-Type and Thymidine Kinase-Deficient Methicillin-Resistant Staphylococcus aureus Isolates in an In Vitro Fibrin Clot Model
Entenza et al.
Antimicrob. Agents Chemother. 2009;53:3635-3641.
ABSTRACT | FULL TEXT